JPMorgan raised the firm’s price target on Cogent Biosciences (COGT) to $67 from $65 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Reports Positive Clinical Trial Results
- Cogent Biosciences price target raised to $48 from $45 at Jefferies
- Cogent Biosciences announces results of APEX trial of bezuclastinib
- Cogent Biosciences presents full SUMMIT results of bezuclastinib
- Cogent Biosciences Completes $230M Convertible Notes Offering